Literature DB >> 7928058

Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen.

E G Silva1, C S Tornos, M Follen-Mitchell.   

Abstract

We reviewed the clinical history and pathology material of 72 patients seen at the M. D. Anderson Cancer Center who developed malignant neoplasms of the uterine corpus after being treated for breast carcinoma with either tamoxifen or other therapeutic regimens. The purpose of this study was to investigate the type of malignant tumors seen in the uterus, their association with endometrial polyps or hyperplasia, and their possible relationship to tamoxifen treatment. This study shows that in patients treated for breast carcinoma, the uterine malignancies are characterized by several features: (a) a previously unreported high incidence of clear cell carcinoma (14 cases) and leiomyosarcoma (12 cases); (b) seven of 12 leiomyosarcomas with unusual features, such as epithelioid (5), tubular (1), and myxoid features (2); (c) a higher incidence of serous carcinoma (45% in patients treated for > or = 12 months); (d) endometrial polyps associated with carcinoma more often than endometrial hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7928058     DOI: 10.1097/00004347-199407000-00009

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  14 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer.

Authors:  Koji Yamazawa; Yukimasa Miyazawa; Masato Suzuki; Maki Wakabayashi; Hiroshi Kaku; Hideo Matsui; Souei Sekiya
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 3.  My approach to the interpretation of endometrial biopsies and curettings.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

Review 4.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

5.  Uterine stromal sarcoma following tamoxifen treatment.

Authors:  T W Beer; R Buchanan; C H Buckley
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

6.  Hormone dependency in metastatic low-grade leiomyosarcoma following uterine smooth muscle tumour of uncertain malignant potential.

Authors:  Cesar Serrano; Marisa R Nucci; Sree H Tirumani; Chandrajit P Raut; Suzanne George
Journal:  BMJ Case Rep       Date:  2014-03-27

Review 7.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

8.  Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.

Authors:  I Cohen; E Perel; D Flex; R Tepper; M M Altaras; M Cordoba; Y Beyth
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

9.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2009-11-24       Impact factor: 5.482

10.  Tumorigenic effects of tamoxifen on the female genital tract.

Authors:  Kaei Nasu; Noriyuki Takai; Masakazu Nishida; Hisashi Narahara
Journal:  Clin Med Pathol       Date:  2008-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.